Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Functional analysis of STAT3 activating mutations in LGL leukemia reveals epigenetic reprograming and therapeutic vulnerabilities.

Zachary Hutchins, Robyn Keller, Molly Halloran, Colleen Isabelle, Kathleen McConnell, Amy Boles, Maria Altemus, Rachel Burzinski, Giulia Calabretto, Nitin Chakravarti, Jonathan Brammer, Anjali Mishra

Blood (2025) 146 (Supplement 1): 5035.

https://doi.org/10.1182/blood-2025-5035

Published: 2025

Journal Articles

A multicenter, open-label phase 1 study of INCB160058, a first-in-class JAK2V617F mutant–selective inhibitor, in patients with myelofibrosis, polycythemia vera, or essential thrombocythemia

Jason Gotlib, John Mascarenhas, Raajit Rampal, Abdulraheem Yacoub, Hongfei Li, Josu Santamaria, Molly Halloran, Naveen Pemmaraju

Blood (2025) 146 (Supplement 1): 2051.

https://doi.org/10.1182/blood-2025-2051

Published: 2025

Journal Articles

Assessment of Concurrent Personal and Family History of Hematologic Malignancies in Patients Referred for Genetic Counseling at Thomas Jefferson University Hospital (TJUH), Sidney Kimmel Cancer Center (SKCC) from 2014-2021

Molly Halloran, Gina Keiffer, Veda Giri, Laura Gross, Lindsay Wilde, Neil Palmisiano, Pierluigi Porcu, Margaret Kasner

Blood (2022) 140 (Supplement 1): 11466–11467.

https://doi.org/10.1182/blood-2022-165510

Published: 2022

Journal Articles

Socioeconomic Influences on the Treatment and Outcomes of Patients with Acute Myeloid Leukemia: Experience from an Urban Academic Center

Jonathan Pan, MD, Sushil Ghimire, MD, Molly Halloran, MD, Alexander Xu, BA, Tingting Zhan, PhD, Gina Keiffer, MD, Lindsay Wilde, MD, Neil Palmisiano, MDMS, Margaret Kasner, MDMSc, Adam F. Binder, MD

Blood (2020) 136 (Supplement 1): 24.

https://doi.org/10.1182/blood-2020-143146

Published: 2020

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Functional analysis of STAT3 activating mutations in LGL leukemia reveals epigenetic reprograming and therapeutic vulnerabilities.

A multicenter, open-label phase 1 study of INCB160058, a first-in-class JAK2V617F mutant–selective inhibitor, in patients with myelofibrosis, polycythemia vera, or essential thrombocythemia

Assessment of Concurrent Personal and Family History of Hematologic Malignancies in Patients Referred for Genetic Counseling at Thomas Jefferson University Hospital (TJUH), Sidney Kimmel Cancer Center (SKCC) from 2014-2021

Socioeconomic Influences on the Treatment and Outcomes of Patients with Acute Myeloid Leukemia: Experience from an Urban Academic Center

Email alerts

ASH Publications

American Society of Hematology

Update search

Functional analysis of STAT3 activating mutations in LGL leukemia reveals epigenetic reprograming and therapeutic vulnerabilities.

A multicenter, open-label phase 1 study of INCB160058, a first-in-class JAK2V617F mutant–selective inhibitor, in patients with myelofibrosis, polycythemia vera, or essential thrombocythemia

Assessment of Concurrent Personal and Family History of Hematologic Malignancies in Patients Referred for Genetic Counseling at Thomas Jefferson University Hospital (TJUH), Sidney Kimmel Cancer Center (SKCC) from 2014-2021

Socioeconomic Influences on the Treatment and Outcomes of Patients with Acute Myeloid Leukemia: Experience from an Urban Academic Center

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only